Elanco divests two business lines for $230M to clear path for Bayer deal
In an effort to win approval for the acquisition of Bayer AG's animal health business, Elanco Animal Health Inc. announced it will divest two products from its portfolio totaling nearly $60 million in annual revenue. On Monday, Elanco (NYSE: ELAN) announced it would sell Capstar, an oral tablet that kills fleas in dogs and cats, to pet medication and wellness company PetIQ Inc. (Nasdaq: PETQ) for $95 million. Capstar generated $28.5 million in revenue for Elanco in 2018. Last week, Elanco also… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 13, 2020 Category: Pharmaceuticals Authors: Lily Lieberman Source Type: news

EU Clears AbbVie Takeover of Allergan Subject to Conditions EU Clears AbbVie Takeover of Allergan Subject to Conditions
The European Commission said on Friday it had approved U.S. drugmaker AbbVie's planned $63 billion acquisition of Botox-maker Allergan, subject to conditions.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Clinical leaders appointed ahead of six-way CCG merger
Nottingham and Nottinghamshire Clinical Commissioning Group has appointed clinical leaders ahead of the formal merger of six CCGs. (Source: HSJ)
Source: HSJ - January 13, 2020 Category: UK Health Source Type: news

HCA buys Texas company with Martin Ventures ties
HCA Healthcare Inc. ventured to Texas for its latest acquisition, but the purchase has roots in HCA's hometown. The Nashville hospital giant announced Jan. 10 that it purchased health care cost-management company Valify. The Frisco, Texas-based firm is backed by former Nashville hospital executive Charlie Martin’s investment firm, Martin Ventures. Terms of the deal were not disclosed in a news release. H CA (NYSE: HCA) is familiar with Valify: In 2018, Valify bought Nashville-based Lucro, a company… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 10, 2020 Category: Biotechnology Authors: Joel Stinnett Source Type: news

HCA buys Texas company with Martin Ventures ties
HCA Healthcare Inc. ventured to Texas for its latest acquisition, but the purchase has roots in HCA's hometown. The Nashville hospital giant announced Jan. 10 that it purchased health care cost-management company Valify. The Frisco, Texas-based firm is backed by former Nashville hospital executive Charlie Martin’s investment firm, Martin Ventures. Terms of the deal were not disclosed in a news release. H CA (NYSE: HCA) is familiar with Valify: In 2018, Valify bought Nashville-based Lucro, a company… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 10, 2020 Category: Pharmaceuticals Authors: Joel Stinnett Source Type: news

Medtech in a Minute: A Huge Merger Flop, a TAVR Breakthrough, and More
Illumina-PacBio Merger Axed Illumina and PacBio called off a $1.2 billion merger after FTC ran interference, saying the pairing could create a monopoly in the next-generation sequencing market. Illumina will now pay PacBio a termination fee of $98 million.   Breakthrough Device Designation Signals a Promising Year for TAVR FDA granted JenaValve a breakthrough device designation for pericardial transcatheter aortic valve replacement (TAVR) system, signaling another promising year for the space. The designation is for severe aortic regurgitation (AR) and AR-dominant mixed aorti...
Source: MDDI - January 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Behind the Deal: How StemBioSys' new acquisition can drive more collaboration
The transaction is already drawing interest from others in the biotech industry who could create more commercial opportunities for the Alamo City company. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 10, 2020 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

Partners to meet with New Hampshire regulators over Exeter acquisition
The on-again, off-again plan for Partners HealthCare to acquire a second New Hampshire hospital may be on again next month. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 10, 2020 Category: Pharmaceuticals Authors: Jessica Bartlett Source Type: news

Lilly Announces Agreement to Acquire Dermira
Lilly to acquire Dermira for $1.1 billion, expanding its portfolio of Phase 3 medicines with the addition of lebrikizumab, an IL-13antibody being studied in Phase 3 for the treatment of moderate-to-severe atopic dermatitis Acquisition also includes QBRE... Biopharmaceuticals, Dermatology, Mergers & Acquisitions Eli Lilly, Dermira , lebrikizumab, atopic dermatitis, QBREXZA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 10, 2020 Category: Pharmaceuticals Source Type: news

Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim's leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company's extensive range of therapeutic antibodies targeting this pathway. (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Nashville-area health care firm buys two Valley businesses
The Tennessee company was looking to establish a foothold in the Arizona market with the acquisitions. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 9, 2020 Category: Biotechnology Authors: Joel Stinnett Source Type: news

Nashville-area health care firm buys two Valley businesses
The Tennessee company was looking to establish a foothold in the Arizona market with the acquisitions. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 9, 2020 Category: Pharmaceuticals Authors: Joel Stinnett Source Type: news

Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of the U.S. biotech company, Bristol's chief medical officer said. (Source: Reuters: Health)
Source: Reuters: Health - January 9, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Net Health names new CEO
Net Health named Josh Pickus as CEO of the Pittsburgh-based medical technology company. The previous CEO, Anthony Sanzo, has been named executive chairman in the transition that was put into motion with the acquisition of Optima Healthcare Solutions, where Pickus was CEO. Sanzo had been CEO since 2012. Pickus has been president and chief integration officer at Net Health since the a cquisition, and before that had been CEO in residence at Alpine Investors. "He is committed to meeting the needs… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 9, 2020 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
IRVINE, Calif., Jan. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Bioniz Therapeutics, Inc., a privately held clinical stage biopharmaceutical company developing first-in-class multi-cytokine peptide therapeutics for the treatment of immuno-inflam... Biopharmaceuticals, Dermatology, Mergers & Acquisitions Bioniz Therapeutics, Almirall (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 9, 2020 Category: Pharmaceuticals Source Type: news

Fibrotic diseases partnership with Enleofen
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases  Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio  Boehringer Ingelheim aims to develop therapies for multiple fibrotic human disorders, including non-alcoholic steatohepatitis (NASH) and interstitial lung diseases (ILDs)Singapore-based Enleofen to receive in excess of one billion USD per product in upfront and success-based development and commercialization milestones (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2020 Category: Research Source Type: news

Cary drugmaker makes first acquisition with new financial backing
A Triangle drugmaker starting the year with a fresh financial backer has made an acquisition of its own. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

Advantia gains $45M for new women ’s health practice, more M & A
Advantia Health LLC has secured $45 million, following an action-packed year that included two acquisitions and a major expansion. The investment in the Arlington-based women's health group, from New York asset management firm BlueMountain Capital Management LLC, will be used to build a new women’s health practice in the District, slated to encompass obstetrics and gynecology, primary care, mental health and other services. The company did not immediately return a request for more information… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

The effects of open captions in a medical drama on the acquisition of medical terminology about chronic health conditions related to physical injury - Kim HS, Kim K.
We examined the impact of supplementary open captions about medical terminology... (Source: SafetyLit)
Source: SafetyLit - January 8, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Altavant plans to develop OSP-101 for the treatment of bronchiolitis obliterans syndrome, the leading cause of morbidity and mortality in post-lung transplant patients CARY, N.C. and BASEL, Switzerland and WAYNE, Pa., Jan. 8, 2020 -- (Healthcare Sales &... Biopharmaceuticals, Mergers & Acquisitions Altavant Sciences, Onspira Therapeutics, pulmonary arterial hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 8, 2020 Category: Pharmaceuticals Source Type: news

Walgreens first-quarter profit falls nearly 25% on higher costs
Drugstore chain Walgreens Boots Alliance Inc posted a 24.8% drop in quarterly profit on Wednesday, hurt by higher costs related to its acquisition of stores from rival Rite Aid Corp (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

AngioDynamics' latest acquisition will boost $95 million business line
It is the latest in a string of acquisitions for AngioDynamics as chief exec Jim Clemmer refocuses the medical device maker by "carving out significant space in larger and faster growing markets." (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2020 Category: Pharmaceuticals Authors: Robin K. Cooper Source Type: news

Sun Pharma eyes China, Japan markets
Shanghai now plans to steer the company into the specialty business (novel, innovative drugs), and towards expanding markets like China and Japan for growth, both through acquisitions and partnerships. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 7, 2020 Category: Pharmaceuticals Source Type: news

Healthgrades CEO: Why we just made our second major acquisition in a year
The news comes a year after Denver-based Healthgrades acquired Birmingham-based Influence Health. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 7, 2020 Category: Pharmaceuticals Authors: Jensen Werley Source Type: news

HCA closes deal to buy one of the nation's largest nursing schools
HCA Healthcare Inc. took another step in the expansion of its nursing empire on Tuesday. The Nashville-based hospital operator closed a deal to buy the majority ownership of Galen College of Nursing, according to a news release. Terms of the deal were not disclosed. HCA announced its plans to buy Galen, which is one of the nation's largest private nursing schools, in March. The Louis ville-based school has 5,000 students enrolled across five campuses nationwide and its online program.  The acquisition… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 7, 2020 Category: Pharmaceuticals Authors: Joel Stinnett Source Type: news

AtriCure Completes Patient Enrollment for aMAZE Trial
AtriCure is rolling into the new year with some significant milestones that help reinforce the presence it has built in the cardiovascular space. The company has been at the forefront of the space in the past – by receiving significant investor attention for its work in atrial fibrillation (Afib) and left atrial appendage (LAA) management. Back in 2018, AtriCure was featured prominently in a report detailing the 25 Most Attractive Medtech Companies on the M&A Radar from Needham & Co analyst Mike Matson. Now just a few short days into the new year, the Mason, OH-based company showed why it has alwa...
Source: MDDI - January 7, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Edge Pharmacy Holdings, LP Completes Acquisition of Edge...
As a leader in the allergy immunotherapy space, Edge Pharmacy Holdings, LP continues rapid expansion through acquisition of Edge Pharmaceuticals, LLC.(PRWeb January 07, 2020)Read the full story at https://www.prweb.com/releases/edge_pharmacy_holdings_lp_completes_acquisition_of_edge_pharmaceuticals_llc/prweb16817458.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 7, 2020 Category: Pharmaceuticals Source Type: news

Vascular Graft Solutions Acquires the Intellectual Property Developed by Kipsbay Medical Inc.
TEL AVIV, Israel, Jan. 6, 2020 -- (Healthcare Sales & Marketing Network) -- Vascular Graft Solutions (VGS) announces on the acquisition of several patent families from NEOGRAFT Technologies Inc. which include patents that were previously developed and own... Devices, Interventional, Acquisitions Vascular Graft Solutions, NEOGRAFT Technologies, Kipsbay Medical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 6, 2020 Category: Pharmaceuticals Source Type: news

Valley cannabis company to pay $35M for Nevada cultivation facility
Including several other recent announced acquisitions, Harvest Health will have one of the largest footprints in the U.S. in 2020, with rights to operate more than 210 facilities. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2020 Category: Biotechnology Authors: Angela Gonzales Source Type: news

Valley cannabis company to pay $35M for Nevada cultivation facility
Including several other recent announced acquisitions, Harvest Health will have one of the largest footprints in the U.S. in 2020, with rights to operate more than 210 facilities. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 4, 2020 Category: Pharmaceuticals Authors: Angela Gonzales Source Type: news

This Reston telemedicine firm has big plans for 2020. It starts with a fresh $15M.
SOC is now armed with fresh funding for a potential acquisition. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 3, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

This Reston telemedicine firm has big plans for 2020. It starts with a fresh $15M.
SOC is now armed with fresh funding for a potential acquisition. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 3, 2020 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news

Illumina and Pacific Biosciences call off merger
Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 3, 2020 Category: Pharmaceuticals Source Type: news

Illumina and PacBio Call it Quits on $1.2B Merger
Illumina and Pacific Biosciences (PacBio) are calling off their $1.2 billion merger. The move comes shortly after the Federal Trade Commission (FTC) sharply criticized the deal, saying it could cause a monopoly in the U.S. market for next-generation sequencing (NGS). Because the deal is ending prematurely, San Diego, CA-based Illumina will now pay PacBio a termination fee of $98 million.Illumina first announced it would acquire PacBio – a longtime rival, in November of 2018. In a release, the companies said the reason for ending the deal is because of the “lengthy regulatory approval pro...
Source: MDDI - January 3, 2020 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news

Hospital Mergers Don't Show Quality Benefit Hospital Mergers Don't Show Quality Benefit
Researchers say study findings further question previous challenges to arguments that hospital consolidation — which has been shown to increase prices — also improves quality.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 3, 2020 Category: Cardiology Tags: Internal Medicine News Source Type: news

Elderwood's Weinberg acquisition creeps along
The acquisition includes seven different corporations, some of which have not yet been approved for sale. The asset purchase agreement stipulates that Elderwood will not gain control of the campus until all approvals are final. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 3, 2020 Category: Pharmaceuticals Authors: Tracey Drury Source Type: news

More hospitals are merging, but health care isn't improving
Quality of care tends to suffer after a merger, challenging industry's stance about the benefits of consolidation. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 2, 2020 Category: Consumer Health News Source Type: news

Cecil County hospital joins Delaware health system
ChristianaCare is expanding its reach into Maryland with the addition of Union Hospital. The Delaware health system and Affinity Health Alliance, the parent organization for Cecil County's Union Hospital, said Thursday they have reached a final merger agreement. Terms of the deal were not disclosed. Union Hospital — a 72-bed hospital in Elkton — and its affiliates join Christi anaCare’s two other hospitals in Delaware: Christiana Hospital in Newark and Wilmington Hospital in Wilmington.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 2, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

Patient Experiences Modestly Worse After Hospital Acquisition
No significant differential changes found in 30 - day readmission rates or 30 - day mortality (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - January 2, 2020 Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news

Patient satisfaction may decline after hospital acquisition
(Reuters Health) - Medicare quality-of-care data reveal that when a hospital is acquired by another hospital or hospital system, readmission and mortality rates are not affected but patient satisfaction deteriorates modestly. (Source: Reuters: Health)
Source: Reuters: Health - January 1, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Patient Satisfaction May Decline after Hospital Acquisition
Summarizes a report which found that patient experience satisfaction decreases at hospitals that have been acquired by other health systems. Analyzes how mergers and acquisitions can affect access to services and quality of care. (Source: News stories via the Rural Assistance Center)
Source: News stories via the Rural Assistance Center - January 1, 2020 Category: Rural Health Source Type: news

Big exec payouts, lawsuits mark gene therapy company's $3.1 billion merger deal
From Astellas' initial interest to the close of the deal took six months. But talks turned intense — and another suitor emerged — before the deal was struck Dec. 2. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 31, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

Big exec payouts, lawsuits mark gene therapy company's $3.1 billion merger deal
From Astellas' initial interest to the close of the deal took six months. But talks turned intense — and another suitor emerged — before the deal was struck Dec. 2. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 31, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

XBiotech sells new drug candidate for $750M to Johnson & Johnson subsidiary
Janssen Pharmaceutical Cos., a subsidiary of Johnson& Johnson, just completed its $750 million acquisition of the rights to bermekimab, a new drug candidate being studied as a potential treatment for multiple dermatological conditions, from Austin-based XBiotech Inc. The deal, announced Dec. 30, will also involve an undisclosed number of employees from XBiotech (Nasdaq: XBIT) joining Janssen’s staff. Under the terms of the agreement, XBiotech may be eligible to receive additional payments of… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 31, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

XBiotech sells new drug candidate for $750M to Johnson & Johnson subsidiary
Janssen Pharmaceutical Cos., a subsidiary of Johnson& Johnson, just completed its $750 million acquisition of the rights to bermekimab, a new drug candidate being studied as a potential treatment for multiple dermatological conditions, from Austin-based XBiotech Inc. The deal, announced Dec. 30, will also involve an undisclosed number of employees from XBiotech (Nasdaq: XBIT) joining Janssen’s staff. Under the terms of the agreement, XBiotech may be eligible to receive additional payments of… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 31, 2019 Category: Biotechnology Authors: John George Source Type: news

Hardy Diagnostics Unveils Universal Transport Medium Product Line
Strategic acquisition enables Hardy Diagnostics to introduce complete line of HealthLink Universal Transport Medium® just in time for flu season SANTA MARIA, Calif., Dec. 31, 2019 -- (Healthcare Sales & Marketing Network) -- Universal Transport Med... Diagnostics, Product Launch Hardy Diagnostics, Universal Transport Medium (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 31, 2019 Category: Pharmaceuticals Source Type: news

Hear it, fear it: fear generalizes from conditioned pictures to semantically related sounds - Gerdes ABM, Fraunfelter L, Alpers GW.
Fear generalization is thought to be an important mechanism in the acquisition and maintenance of anxiety disorders. Previous studies have investigated fear generalization within one sensory modality - mainly within the visual domain. However, a growing bo... (Source: SafetyLit)
Source: SafetyLit - December 31, 2019 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Court orders Boston Scientific to complete $275M acquisition
Boston Scientific Corp. could be forced to go through with a $275 million acquisition that the Marlborough-based medical device giant had abandoned following a fraud investigation. Boston Scientific (NYSE: BSX) struck a deal in 2017 to purchase California medical device company Channel Medsystems Inc., and then called off the deal last year after finding out that one Channel’s executives had falsified paperwork, including portions of Channel’s FDA application for its fir st product. But a Delaware… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 30, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Court orders Boston Scientific to complete $275M acquisition
Boston Scientific Corp. could be forced to go through with a $275 million acquisition that the Marlborough-based medical device giant had abandoned following a fraud investigation. Boston Scientific (NYSE: BSX) struck a deal in 2017 to purchase California medical device company Channel Medsystems Inc., and then called off the deal last year after finding out that one Channel’s executives had falsified paperwork, including portions of Channel’s FDA application for its fir st product. But a Delaware… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 30, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

MedCare makes acquisition
Pittsburgh-based MedCare Equipment Co., a home medical equipment and respiratory therapy services company, will be expanding with an acquisition Jan. 1. MedCare will be purchasing the assets of the home medical equipment and respiratory therapy units of Somerset Med Services. The combined company will have revenue of about $156 million with operations in Pennsylvania, Ohio, West Virginia and New York. MedCare has partnerships with Excela Health, C onemaugh Health System, Heritage Valley Health System,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 30, 2019 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news